Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Recursion Pharmaceuticals, Inc. on June 14, 2022. The filing details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events rather than financial performance.
Material Changes
No material financial changes are reported in this document. The primary event is the completion of the annual stockholder vote.
Outlook, Risks, and Voting Results
Meeting Attendance: Approximately 81.88% of the combined voting power was present virtually or by proxy, constituting a quorum. Voting involved 118,818,276 shares of Class A common stock and 8,269,209 shares of Class B common stock (which carry 10 votes per share).
Proposal 1: Election of Class I Directors
- Zachary Bogue, J.D.: Elected (155,532,902 votes for; 9,276,806 withheld).
- Zavain Dar: Elected (149,499,724 votes for; 15,309,984 withheld).
- Robert Hershberg, M.D., Ph.D.: Elected (145,878,263 votes for; 18,931,445 withheld).
Proposal 2: Ratification of Auditor
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 201,362,410
- Votes Against: 112,434
- Abstentions: 35,522
Investor Verification Checklist
- Verify the terms of office for the newly elected Class I directors (serving until the 2025 annual meeting).
- Confirm the engagement of Ernst & Young LLP for the 2022 fiscal year audit.
- Review the definitive proxy statement filed on April 28, 2022, for detailed biographies of directors and further context on the proposals.
- Note the significant number of broker non-votes (36,700,658) on the director election, indicating shares held by brokers that were not voted on this matter.